Status:
COMPLETED
Single-dose Crossover Study to Evaluate the Early Bronchodilating Effect of FlutiForm HFA pMDI in Adult Subjects With Mild to Moderate Asthma
Lead Sponsor:
SkyePharma AG
Collaborating Sponsors:
Abbott
Conditions:
Mild to Moderate Asthma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The primary purpose of this study is to evaluate the early bronchodilating effect of SKP FlutiForm HFA pMDI compared to placebo.
Eligibility Criteria
Inclusion
- Subjects with documented history of mild to moderate asthma currently taking a stable dose of inhaled corticosteroid
Exclusion
- Participation in a prior FlutiForm study
- Smoking history within the last 12 months,
- Significant, non-reversible, pulmonary disease
- Life-threatening asthma within the last year
Key Trial Info
Start Date :
September 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2008
Estimated Enrollment :
39 Patients enrolled
Trial Details
Trial ID
NCT00734292
Start Date
September 1 2008
End Date
October 1 2008
Last Update
August 27 2010
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Investigational Site
Anaheim, California, United States, 92801
2
Investigational Site
Mission Viejo, California, United States, 92691
3
Investigational Site
Denver, Colorado, United States, 80230
4
Investigational Site
Valrico, Florida, United States, 33594